Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1116

Sort by

Sort Order Select

Journal Articles

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Konstantinos Tzelepis, Etienne De Braekeleer, PhD MSc, Eliza Yankova, PhD, Justyna Rak, PhD, Demetrios Aspris, MSc, Ana Filipa Domingues, PhD, Richard Fosbeary, Alan Hendrick, PhD, Dan Leggate, PhD, Yaara Ofir-Rosenfeld, PhD, Alexandra Sapetschnig, PhD, Cristina Pina, MDDPhil, Mark Albertella, PhD, Wesley Blackaby, PhD, Oliver Rausch, PhD, George S. Vassiliou, FRCPath, MRCP, PhD, Tony Kouzarides, PhD

Blood (2019) 134 (Supplement_1): 403.

https://doi.org/10.1182/blood-2019-127962

Published: 2019

Journal Articles

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Paola Neri, MD PhD, Ranjan Maity, PhD, Jean-Baptiste Alberge, Sarthak Sinha, BSc, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 572.

https://doi.org/10.1182/blood-2019-127593

Published: 2019

Journal Articles

Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro

Qing Li, MD, Yunfan Yang, MD, Yu Wu, MD

Blood (2019) 134 (Supplement_1): 536.

https://doi.org/10.1182/blood-2019-123876

Published: 2019

Journal Articles

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Yihong Guan, PhD, Bhumika J. Patel, MD, Metis Hasipek, PhD, Dale Grabowski, BS, Hassan Awada, MD, Cassandra M Kerr, MS, Valeria Visconte, PhD, Aziz Nazha, MD, Yogenthiran Saunthararajah, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 453.

https://doi.org/10.1182/blood-2019-131525

Published: 2019

Journal Articles

Pharmacological Inhibition of Nemo-like Kinase Rescues mTOR-Mediated Translation and Primes Progenitors for Leucine-Stimulated Erythroid Expansion in Pre-Clinical Models of Diamond Blackfan Anemia

Mark C Wilkes, PhD, Jacqueline D Mercado, Mallika Saxena, Jun Chen, MD PhD, Kavitha Siva, PhD, Hee-Don Chae, PhD, Minyoung Youn, PhD, Ethan Patrick Wentworth, Kevin Jung, Ryan Sathianathen, Hiral Patel, Bertil Glader, MD PhD, Anupama Narla, MD, Claire E Repellin, PhD, Hanna T Gazda, MD PhD, Manuel Serrano, PhD, Johan Flygare, MD PhD, Kathleen M. Sakamoto, MD PhD

Blood (2019) 134 (Supplement_1): 455.

https://doi.org/10.1182/blood-2019-129570

Published: 2019

Journal Articles

HDAC8 Promotes MLL-Rearranged Acute Myeloid Leukemia By Inhibiting p53 Acetylation

Dijiong Wu, MD, Man Li, PhD, Lianjun Zhang, PhD, Jing Qi, PhD, Chun-Wei David Chen, PhD, Xin He, PhD, Yinghui Zhu, PhD, Haojie Dong, PhD, Jie Sun, PhD, Ling Li, PhD, Guido Marcucci, MD, Ya-Huei Kuo, PhD

Blood (2019) 134 (Supplement_1): 642.

https://doi.org/10.1182/blood-2019-124134

Published: 2019

Journal Articles

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

Deyi Zhang, PhD, Hailey Harris, Aileen Kelly, PhD, Daniel W Robbins, May Tan, Timothy Ingallinera, Neil Bence, Arthur T Sands, Sivasubramanian Baskar, Sarah E. M. Herman, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 174.

https://doi.org/10.1182/blood-2019-126921

Published: 2019

Journal Articles

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Fiona Brown, BS, Yang Zhang, PhD, Claire Hinterschied, Alexander Prouty, BS, Shelby Sloan, BS, JoBeth Helmig-Mason, Msc, Ji Hyun Chung, PhD, Kris Vaddi, PhD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Lapo Alinari, MD PhD, Peggy Scherle, PhD, Rosa Lapalombella, PhD, Jihye Paik, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 302.

https://doi.org/10.1182/blood-2019-130797

Published: 2019

Journal Articles

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

Zuzana Chyra, PhD, Maria Gkotzamanidou, MD PhD, Masood A. Shammas, PhD, Vassilis L. Souliotis, PhD, Yan Xu, MD, Mehmet K. Samur, PhD, Aaron B. Beeler, PhD, Roman Hajek, MD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4385.

https://doi.org/10.1182/blood-2019-130700

Published: 2019

Journal Articles

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

Changnian Liu, PhD MD, Bin Liu, MSc, Chunping Xu, PhD, Pan Zhang, Bin Li, Bin Ji, Bin Zhang, Qingjun Liu, PhD, James Zhang, MSc, Chengzhi Yu, PhD

Blood (2019) 134 (Supplement_1): 5141.

https://doi.org/10.1182/blood-2019-123589

Published: 2019

Journal Articles

The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells

Andrea Ghelli Luserna Di Rorà, PhD, Antonella Padella, PhD, Maria Chiara Fontana, PhD, Eugenio Fonzi, PhD, Anna Ferrari, PhD, Enrica Imbrogno, PhD, Martina Ghetti, PhD, Roberta Napolitano, PhD, Maria Teresa Bochicchio, Giovanni Martinelli, MD, Giorgia Simonetti, PhD

Blood (2019) 134 (Supplement_1): 5047.

https://doi.org/10.1182/blood-2019-129964

Published: 2019

Journal Articles

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Kazuharu Kamachi, MD, Hiroshi Ureshino, MD, Nao Yoshida, MD, Yuki Kurahashi, Tatsuro Watanabe, PhD, Seiji Okada, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 5365.

https://doi.org/10.1182/blood-2019-125460

Published: 2019

Journal Articles

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Li Chen, PhD, Amit Kumar Mitra, PhD MSc, BSc

Blood (2019) 134 (Supplement_1): 5543.

https://doi.org/10.1182/blood-2019-131923

Published: 2019

Journal Articles

Targeting Nucleolin for Reversal of Chemotherapy Resistance in Acute Lymphoblastic Leukemia

Jianda Hu, PhD, Yanxin Chen, MD PhD, Zhengjun Wu, Lingyan Wang, PhDMD, Jingjing Wen, Peifang Jiang, Yun Zhang, Minhui Lin, MD PhD

Blood (2019) 134 (Supplement_1): 5058.

https://doi.org/10.1182/blood-2019-127073

Published: 2019

Journal Articles

Apatinib Exhibits Cytotoxicity to Acute Myeloid Leukemia Cell Via Targeting VEGFR2-Mediated Pro-Survival Signaling and Angiogenesis

Lian Yu, Manman Deng, Zhifeng Li, Zhihong Fang, Yun Dai, MD, Bing Xu

Blood (2019) 134 (Supplement_1): 5158.

https://doi.org/10.1182/blood-2019-123472

Published: 2019

Journal Articles

High Expression of BCAT1 promotes Acute Myeloid Leukemia Progression and Sensitize to PARP Inhibitor

Jie Jin, PhD, Jie Jin, PhD, Jiajia Pan, Yungui Wang, PhD, Shujuan Huang, Shihui Mao, Qing Ling, Jinghan Wang, MD PhD, Chenying Li

Blood (2019) 134 (Supplement_1): 5041.

https://doi.org/10.1182/blood-2019-125221

Published: 2019

Journal Articles

Melatonin Increases the Chemosensitivity of Diffuse Large B Cell Lymphoma Cells to Epirubicin By Inhibiting P-Glycoprotein Expression Via the NF-Κb Pathway

Xiuhua Sun, MD, Hong Qin, MD PhD

Blood (2019) 134 (Supplement_1): 5064.

https://doi.org/10.1182/blood-2019-128271

Published: 2019

Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC

Blood (2019) 134 (Supplement_1): 5324.

https://doi.org/10.1182/blood-2019-128604

Published: 2019

Journal Articles

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Narjis Fatima, BSMedTech,MPhil, Richard Christopherson, PhDEmeritus Professor, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2019) 134 (Supplement_1): 5443.

https://doi.org/10.1182/blood-2019-130082

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Deborah A. Katz, MD, Matthew S. McKinney, MD

Blood (2019) 134 (Supplement_1): 5322.

https://doi.org/10.1182/blood-2019-124890

Published: 2019

NARROW

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Pharmacological Inhibition of Nemo-like Kinase Rescues mTOR-Mediated Translation and Primes Progenitors for Leucine-Stimulated Erythroid Expansion in Pre-Clinical Models of Diamond Blackfan Anemia

HDAC8 Promotes MLL-Rearranged Acute Myeloid Leukemia By Inhibiting p53 Acetylation

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Targeting Nucleolin for Reversal of Chemotherapy Resistance in Acute Lymphoblastic Leukemia

Apatinib Exhibits Cytotoxicity to Acute Myeloid Leukemia Cell Via Targeting VEGFR2-Mediated Pro-Survival Signaling and Angiogenesis

High Expression of BCAT1 promotes Acute Myeloid Leukemia Progression and Sensitize to PARP Inhibitor

Melatonin Increases the Chemosensitivity of Diffuse Large B Cell Lymphoma Cells to Epirubicin By Inhibiting P-Glycoprotein Expression Via the NF-Κb Pathway

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only